Morales PDM, Villalobos ACP, Gamboa CJR, Pavía RN

Language: Spanish
References: 25
Page: 11-16
PDF size: 180.39 Kb.

ABSTRACT

BCG (Bacillus Calmette-Guérin) vaccine administration is recommended in our country for newborns, to protect them against disseminated disease. In HIV (Human Immunodeficiency Virus) infected children this protection is unclear, and vaccination has been associated with local complications and disseminated infection.
Material and methods. We reviewed 289 medical records of patients diagnosed with HIV infection, followed at Hospital Infantil de Mexico Federico Gómez during the period January 1997-April 2010, describing the secondary complications of BCG vaccine.
Results. 2.4% of the study population developed complications secondary to BCG vaccine, 6 patients had ipsilateral lymphadenitis, a fistula was observed in two cases and in one a papular lesion case. All were under highly active antiretroviral therapy (HAART), 6 cases did not receive antituberculous treatment and were monthly reviewed, and 1 patient received antituberculous treatment. There was no disease dissemination nor mortality in these cases, and all evolved towards improvement.
Conclusions. Clinical surveillance during the first months after starting HAART, is important in patients infected with HIV/AIDS who received BCG vaccine at birth.

REFERENCES

1. Manual de vacunación 2008-2009. Consejo Nacional de Vacunación. http://www.censia.salud.gob.mx/interior/ vacunacion/vacunacion_index.html

2. Mansoor, et al. “HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin Vaccine. The Journal of Infectious Diseases 2009; 199: 982-90.

3. Hesseling AC, et al. “Diseminated bacilli Calmette-Guérin disease in HIV-infectad South African infants”. Bull World Health Organ 2009; 87: 505-511.

4. Moss WJ, Clemens CJ, Halsey NA. “Immunization of children at risk of infections with human immunodeficiency virus”. Bull World Health Organ 2003; 81: 61-70.

5. Puthanakit T, Oberdorfer P, Punjaisee S, Wannarit P, Sirisanthana T, Sirisanthana V. “Immune reconstitution syndrome due to Bacillus Calmette-Guérin after Initiation of antirretroviral therapy in children with HIV infection”. CID 2005; 41: 1049-1052.

6. Cohen JM, Whittaker E, Walters S, Lyall H, Tudor-Williams, Kampmann B. “Presentation, diagnosis and management of tuberculosis in HIV-iInfected children in the UK”. HIV Medicine 2008; 9(5): 277-284.

7. Programa Nacional de TB. “Magnitud y trascendencia (Epidemiología). Guía práctica para la atención de la tuberculosis en niños, niñas y adolescentes.” http:// www.cenave.gob.mx/tuberculosis/WEB/descargas1/ MATERIALES/T%C3%89CNICOS/guia_pediatrica.pdf

8. Dirección General Adjunta de Epidemiología. SSA. Sistema Único de Información para la Vigilancia Epidemiológica. http://www.sinave.gob.mx.

9. Smith K, et al. “Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy”. AIDS 2009; 23: 1097-1107.

10. Talbot EA, Perkins MD, Silva SF, Frothingham R. “Disseminated Bacille Calmette-Guérin disease after caccination: Case report and review”. CID 1997; 24: 1139-1146.

11. Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Scaf HS, et al. “Bacille Calmette-Guérin vaccineinduced disease in HIV-infected and HIV-uninfected children”. CID 2006; 42(15 February): 548-558.

12. “CDC 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age”. MMWR 1994; 43.

13. WHO. TB/HIV: A clinical manual. 2nd. Edition. Depart-ment of HIV/AIDS. Department of Child and Adolescent Health and Develoment, 2004.

14. Norma Oficial Mexicana NOM-036-SSA2-2002. Prevención y control de enfermedades. Aplicación de vacunas, toxoides, sueros, antitoxinas e inmunoglobulinas en el humano.

15. Besnard M, Sauvion S, Offredo C, Gaudelus J, Gaillard JL, et al. “Bacillus Calmette Guérin infection after vaccination of human immunodeficiency virus-infected children”. Pediatr Infect Dis J 1993; 12 :993-997.

16. Deeks S, et al. “Serious adverse events associated with Bacille Calmette-Guérin v”accine in Canada. Pediatr Infect Dis J 2005; 24: 538-541.

17. Goraya JS, Virdi VS. “Bacille Calmette-Guérin lymphadenitis”. Postgrad Med J 2002; 78: 327-329.

18. Nuttall JJ, Davies MA, Hussey GD Eley BS. ”Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy”. Int J Infect Dis 2008; 12: e99-105.

19. Western Cape Department of Health. “Intradermal BCG immunization: information for health workers about the use of intradermal BCG (bacille Calmette-Guerin) vaccine against tuberculosis in the Expanded Programme on Immunization in South Africa”. www.capegateway. gov.2a/eng/your_life/

20. Agusti RS, Santaolalla EP, Pérez TA, Otero RC, Santos DM, Asensi BF. “BCGitis en lactante con inmunodeficiencia adquirida”. Revista de Enfermedades Infecciosas en pediatría 2008; 21 (83): 90-93.

21. Hesseling AC, Caldwell J, Cotton MF, Eley BS, Jaspan HB, et al. “BCG vaccination in South African HIV-exposed infants –risks and benefits”. S Afr Med J 2009 99(2): 88-91. Azzopardi P, Bennett CM, Graham M, Duke T. “Bacille

22. Calmette-Guérin vaccine-related disease in HIV-infected children: a systematic review”. Int J Tuberc Lung Dis 2009; 13 (11): 1331-1344.

23. WHO. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. 2006.

24. Dunkley-TJ, Pierre RB, Steel-DJ, Palmer P, Davis D, et al. Bacille Calmette-Guérin lymphadenitis and Immune Reconstitution Syndrome in HIV-infected children on Antiretroviral Therapy in Jamaica. West Indian Med J 2008; 57(3): 302.

25. WHO. Safety of BCG vaccine in HIV-infected children. 2008. http://www.who.int/vaccine_safety/topics/bcg/ immunocompromised.